Table 6: Ongoing clinical trials that evaluate drug effects on BPV.

Trial denominationObjectiveEndpointClinicalTrials.gov Identifier

Indapamide versus hydrochlorothiazide in elderly hypertensive patients with renal insufficiencyEvaluate the effects of indapamide SR 1.5 mg on renal function, endothelial function, blood pressure variability by comparison with hydrochlorothiazide 25 mg, in patients with mild-to-moderate renal insufficiency and hypertension.Primary outcome measures: renal function
Secondary outcome measures: endothelial function, blood pressure variability
NCT01172431

Compare the effects of Lercanidipine Hydrochloride Tablet (Zanidip) and Felodipine sustained-release tablet for HypertensionCompare felodipine sustained-release tablets to Lercanidipine hydrochloride tablets (Zanidip ) for the treatment of patients with mild-to-moderate primary hypertension and to investigate the influence on patients’ heart rate and blood pressure variability.Primary outcome measures: change from baseline in mean seated diastolic BP in clinical after 6 weeks of treatment
Change from baseline in mean seated systolic BP after 6 weeks of treatment
NCT01520285

ARB and CCB longest combination treatment on ambulatory and home BP in hypertension with atrial fibrillation-multicenter study on time of Dosing (ACROBAT)Evaluate of 24-hour antihypertensive effect of long-acting ARB-CCB tablet administrated to hypertensive patients with atrial fibrillation, and comparison of 24-hour antihypertensive effect of long-acting ARB-CCB tablet between morning administration and bedtime administration.Primary outcome measures: change in 24-hour average BP from baseline to week 12.
Secondary outcome measures:
Change in BP at nighttime, early-morning, and daytime from baseline to Week 12.
Change in BPV from baseline to Week 12.
NCT01748253

Renal sympathetic modification in patients with metabolic syndromeAssess the incident of composite cardiovascular events after renal sympathetic modification using THERMOCOOL catheter in patients with metabolic syndrome, and evaluate safety and efficacy of the intervention.Primary outcome measures: composite cardiovascular events (myocardial infarction, heart failure, sudden death, cardiogenic death)
Secondary outcome measures: effect on glucose and lipid metabolism and BPV

Comparison of bisoprolol with metoprolol succinate sustained-release on heart rate and blood pressure in hypertensive patients (CREATIVE)Demonstrate the superiority and/or noninferiority of bisoprolol on metoprolol succinate sustained-release (SR)Primary outcome measures: change of mean diastolic ABPM in the last 4 hours after 12-week treatment from baseline.
Secondary outcome measures: change of mean ambulatory 24 h, daytime and nighttime BP
24-hour variability of BP
NCT01508325

Source: www.clinicaltrials.gov.